MTDX203 / Montdorex - LARVOL DELTA

Modulating DNA repair through endo-exonuclease inhibition: a new therapeutic paradigm in oncology (AACR 2024) - P2 | "Furthermore, pre-clinical animal studies of our lead candidate, MTDX203, showed an increased anti-cancer activity with a higher safety index than pentamidine...Our work establishes the EE as a therapeutic target for cancer and identifies a new First in Class of novel anti-cancer agents.1Chow et al. (2004) MCT 3:911-9182 NCT01378143: Pentamidine (OCZ103-OS) in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherap"

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Montdorex Announces Acceptance of Its Abstract for Presentation at the AACR Annual Meeting 2024 (Businesswire) - "Montdorex Inc...announced that Terry Chow, Ph.D., Founder and CEO will present insights on the relevance of inhibiting the endo-exonuclease (EE) enzyme in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting...The endo-exonuclease enzyme plays a key role in DNA damage repair mechanisms, but it is also overexpressed in cancer tumors. In a proof-of-concept study, Montdorex showed that tumors with increased EE expression showed the best response to pentamidine, an endo-exonuclease inhibitor. The Company has also identified mono- and di-amidine analogs of pentamidine that are more effective than the parent drug in both in vitro and in vivo studies...Our lead candidate, MTDX203, showed an increased anti-cancer activity with a higher safety index than pentamidine in preclinical animal studies'..."

Preclinical • Solid Tumor